Abstract:In 1992, in an effort to bring novel drugs to market more quickly and meet patient needs in a timely manner, the US Food and Drug Administration (FDA) pioneered an accelerated approval initiative on the basis of surrogate endpoints that are reasonably predictive of clinical benefit for the treatment of serious or life-threatening diseases. 1 US Food and Drug AdministrationAccelerated approval program. https://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approval-programDate accessed: October 24, 2023 Google Scholar By contrast to regular approval, accelerated approval requires post-market confirmatory clinical trials to establish the clinical benefit of the drug, then a decision is made as to whether the approval should be converted to a traditional approval or whether the drug should be withdrawn from the market. 2 US Food and Drug AdministrationExpedited programs for serious conditions––drugs and biologics. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expedited-programs-serious-conditions-drugs-and-biologicsDate accessed: October 24, 2023 Google Scholar In the past 3 years, this expedited pathway has attracted extensive criticism, including failure to complete confirmatory clinical trials in a timely manner, 3 Fashoyin-Aje LA Mehta GU Beaver JA Pazdur R The on- and off-ramps of oncology accelerated approval. N Engl J Med. 2022; 387: 1439-1442 Crossref PubMed Scopus (33) Google Scholar , 4 Gyawali B Kesselheim AS Ross JS The accelerated approval program for cancer drugs—finding the right balance. N Engl J Med. 2023; 389: 968-971 Crossref PubMed Scopus (9) Google Scholar use of surrogate endpoints (eg, progression-free survival) in confirmatory clinical trials, 5 Parikh RB Hubbard RA Wang E et al. Exposure to US cancer drugs with lack of confirmed benefit after US Food and Drug Administration accelerated approval. JAMA Oncol. 2023; 9: 567-569 Crossref PubMed Scopus (6) Google Scholar and failure to withdraw drugs quickly from the markets when they have been shown to not have clinical benefit. 6 Akhade A Sirohi B Gyawali B Global consequences of the US FDA's accelerated approval of cancer drugs. Lancet Oncol. 2022; 23: 201-203 Summary Full Text Full Text PDF PubMed Scopus (10) Google Scholar Concerns have also been raised that cancer drugs given accelerated approval by the FDA could lead to difficult decisions in other countries, especially in some low-income and middle-income countries that do not have their own regulatory agencies or that have weak regulatory capacity. 6 Akhade A Sirohi B Gyawali B Global consequences of the US FDA's accelerated approval of cancer drugs. Lancet Oncol. 2022; 23: 201-203 Summary Full Text Full Text PDF PubMed Scopus (10) Google Scholar , 7 Cramer A Sørup FKH Christensen HR Petersen TS Karstoft K Withdrawn accelerated approvals for cancer indications in the USA: what is the marketing authorisation status in the EU?. Lancet Oncol. 2023; 24: e385-e394 Summary Full Text Full Text PDF PubMed Scopus (3) Google Scholar

Evolving Landscape of New Drug Approval in Japan and Lags from International Birth Dates: Retrospective Regulatory Analysis

An Empirical Analysis of Japan's Drug Development Lag Behind the United States

Different Development Strategies Affecting Japan's Drug lag between Japan-Based and Foreign-Based Companies

Current Regulatory Status in China of Drugs Withdrawn from the US FDA Accelerated Pathway: Implications for Regulation Globally

Two decades of new drug approvals in Japan

Strengthening the Competitiveness of Japan's Pharmaceutical Industry: Analysis of Country Differences in the Origin of New Drugs and Japan's Highly Productive Firm.

Trend Analysis of Regulatory Approvals for Generics and Biosimilars in Japan: 15 Years of PMDA During Fiscal Years 2009–2023

Significant Differences in Drug Lag in Clinical Development Among Various Strategies Used for Regulatory Submissions in Japan

Influence of Expedited Programs in the United States on Oncology Drug Development in Japan

Beef heart mitochondrial F1-ATPase: inhibition by azidoadenyl-5'-yl imidodiphosphates and cooperative binding of substrate.

A Significant Anticancer Drug Approval Lag Between Japan and the United States Still Exists for Minor Cancers

Assessing drug lag in new drug approvals by the Iran Food and Drug Administration compared to the U.S. FDA, EMA, and PMDA: A 20-year analysis (2001–2021)

Drug Lag and Associated Factors for Approved Drugs in Korea Compared with the United States

Receptor-Interacting Protein-2 Deficiency Delays Macrophage Migration and Increases Intracellular Infection during Peritoneal Dialysis-Associated Peritonitis

Assessment of the Delay in Novel Anticancer Drugs between China and the United States: A Comparative Study of Drugs Approved between 2010 and 2021

Paediatric Drug Development in Japan: Current Status and Future Challenges

Impact of Quality by Design Development on the Review Period of New Drug Approval and Product Quality in Japan

Clarifying the Discussion Points in New Drug Application Reviews for Approval in Japan by a Government Advisory Council

New Japanese Regulatory Frameworks for Post-Marketing Management of Pharmaceutical Products

Present State of Knowledge Concerning Effects of the Sulfonylurea Compounds in Diabetes Mellitus: Report of the Committee on Summarization of the Conference

Recent and anticipated novel drug approvals (3Q 2024 through 2Q 2025)